Mechanisms of IL‐17A Neutralisation in Alleviating Renal Fibrosis and Inflammation in Spontaneously Hypertensive Rats
Clinical and Experimental Pharmacology and Physiology · 2026-03 · 53 (3)
DOI: 10.1111/1440-1681.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 11.03.2026. Verfasst von Anshuai Ba und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Hospital of Anhui University of Science and Technology, Huainan, China. Hauptthemen laut MEDLINE: Interleukin-17, Inflammation, Kidney, Antibodies, Neutralizing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Special Cultivation Project of Anhui University of Science and Technology, The Open Fund Project of Anhui Provincial Key Laboratory of Industrial Dust Deep Purification and Occupational Health Safety, Innovative Teaching Team in Physiology and Pathophysiology.
Abstract (Originalsprache)
Objective
This study investigated the therapeutic effects and mechanisms of IL‐17A neutralisation on renal interstitial fibrosis and inflammation in spontaneously hypertensive rats (SHRs).
Methods
SHRs were treated with an IL‐17A‐neutralising antibody (NAb) for 20 weeks. Blood pressure and renal function were monitored. Renal tissues were analysed for histopathology, macrophage polarisation, epithelial‐mesenchymal transition (EMT), inflammatory cytokines, and relevant signalling pathways.
Results
IL‐17A NAb treatment significantly attenuated hypertension progression and improved renal function. It also ameliorated renal fibrosis and histopathological damage. Mechanistically, IL‐17A neutralisation suppressed M2 macrophage polarisation and downregulated the TGF‐β/Smad pathway, an effect associated with attenuated extracellular matrix (ECM) remodelling. This was accompanied by reduced levels of pro‐inflammatory cytokines and inhibition of key inflammatory signalling pathways, including JAK/STAT, PI3K/AKT, and NF‐κB.
Conclusion
Our findings demonstrate that IL‐17A neutralisation alleviates renal fibrosis and inflammation in SHRs. The protective effects are associated with the inhibition of M2 macrophage polarisation, suppression of the TGF‐β/Smad pathway and the associated EMT process, and attenuation of systemic and renal inflammation, concomitant with the coordinated downregulation of the JAK/STAT, PI3K/AKT, and NF‐κB signalling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Hospital of Anhui University of Science and Technology, Huainan, China.
- Anhui University of Science and Technology Medicine School, Huainan, China.
- Mingguang People's Hospital, Chuzhou, China.
- Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes, Huainan, China.
ORCID-Profile: Yu Wang
Förderung
- Medical Special Cultivation Project of Anhui University of Science and Technology
- The Open Fund Project of Anhui Provincial Key Laboratory of Industrial Dust Deep Purification and Occupational Health Safety
- Innovative Teaching Team in Physiology and Pathophysiology
Zitieren
APA
Ba, A., Chen, Z., Wu, M., Li, W., & Wang, Y. (2026). Mechanisms of IL‐17A Neutralisation in Alleviating Renal Fibrosis and Inflammation in Spontaneously Hypertensive Rats. Clinical and Experimental Pharmacology and Physiology, 53(3). https://doi.org/10.1111/1440-1681.70116
Vancouver
Ba A, Chen Z, Wu M, Li W, Wang Y. Mechanisms of IL‐17A Neutralisation in Alleviating Renal Fibrosis and Inflammation in Spontaneously Hypertensive Rats. Clinical and Experimental Pharmacology and Physiology. 2026;53(3). doi:10.1111/1440-1681.70116
BibTeX
@article{Ba2026,
author = {Ba, Anshuai and Chen, Zhenzhen and Wu, Meng and Li, Weiyi and Wang, Yu},
title = {Mechanisms of IL‐17A Neutralisation in Alleviating Renal Fibrosis and Inflammation in Spontaneously Hypertensive Rats},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
volume = {53},
number = {3},
doi = {10.1111/1440-1681.70116}
}
EUVIMED